阴性夜间血球蛋白尿症:解开其分子病原性和推进有针对性的治疗策略
Elisavet Apostolidou1, Vasileios Georgoulis1, Dimitrios Leonardos1
1Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, St. Niarchou Av., 45 500 Ioannina, Greece.
Diseases (Basel, Switzerland)
|September 26, 2025
概括
阴性夜间血红蛋白尿 (PNH) 是一种罕见的血液疾病,由PIGA基因突变引起. 补充抑制剂已经改变了PNH治疗,新的药物提供了更好的结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
背景情况:
- 阴性夜间血红蛋白尿 (PNH) 是一种罕见的获得性克隆性血液学疾病.
- 它源于PIGA基因的体质突变,导致缺少GPI定蛋白质,如CD55和CD59.
- 这种缺失会导致不受控制的补体激活,导致血液溶解,血栓形成和骨髓衰竭.
研究的目的:
- 审查PNH的病理生理学.
- 评估目前和新兴的补充抑制剂用于PNH管理.
- 讨论PNH治疗中的挑战和未来方向.
主要方法:
- 关于PNH病理生理学和补充抑制剂的文献综述.
- 对eculizumab和较新的补充向剂的临床数据的分析.
- 在PNH中讨论治疗结果和未满足的需求.
主要成果:
- 作为C5抑制剂的eculizumab降低了血栓形成的风险,并改善了生存率,但并没有导致贫血.
- 针对近位补充元件的新型药物提供了更广泛的控制和便利.
- 用补充剂抑制剂在PNH管理方面取得了重大进展.
结论:
- 补充抑制剂已经彻底改变了PNH治疗.
- 新兴疗法显示出提高疗效和患者便利性的承诺.
- 持续的研究对于解决PNH的剩余治疗挑战至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
442
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
442
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
589
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
589
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441
Pulmonary Hypertension: Classification and Pathogenesis
576
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
576


